The effective use of the supercritical technology in the production of new pharmaceutical formulations with greater bioavailability requires the determination of the solubility of pharmaceutical substances in supercritical CO₂ (scCO₂) at different conditions. In the current work, the solubility of an antibacterial compound, Gemifloxacin, was measured at various temperatures (308 to 338 K), and pressures (120 to 300 bar). This compound has a poor solubility in scCO₂ (0.02 × 10⁻⁴ to 0.67 × 10⁻⁴ mole fraction or 0.0156 to 0.5891 g.kg⁻¹). Furthermore, some popular empirical models and three thermodynamic approaches (SRK and PR equations of state, and the regular solution model) were applied to correlate and predict the solubility of Gemifloxacin in scCO₂. The regular solution model with temperature-dependent solubility parameter (mean AARD% = 2.32–4.34) and the SRK-based model (mean AARD% = 7.47), exhibited the highest accuracy in fitting the experimental data.

有效利用超临界技术生产具有更高生物利用度的新药物制剂需要测定不同条件下药物物质在超临界CO ₂ (scCO ₂ ) 中的溶解度。在当前的工作中，在不同温度（308 至 338 K）和压力（120 至 300 bar）下测量了抗菌化合物吉米沙星的溶解度。_{该化合物在scCO 2} (0.02×10 ^-4至0.67×10 ^-4摩尔分数或0.0156至0.5891 g.kg ^-1 )中具有差的溶解度。此外，应用一些流行的经验模型和三种热力学方法（SRK和PR状态方程以及正则解模型）来关联和预测吉米沙星在scCO ₂中的溶解度。具有与温度相关的溶解度参数的常规解模型（平均AARD% = 2.32–4.34）和基于 SRK 的模型（平均AARD% = 7.47）在拟合实验数据方面表现出最高的准确度。